What You Should Know:
– Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies.
– Deep 6 AI enables healthcare organizations to de-risk clinical trials, accelerate recruitment, and generate real-world evidence (RWE) with speed and precision. Its AI-powered software matches patients to clinical trials by mining real-time structured and unstructured electronic medical record (EMR) data across a broad ecosystem, which includes academic medical centers, National Cancer Institute (NCI)-Designated Cancer Centers, and NCI Community Oncology Research Programs.
Tempus Expands Precision Medicine Capabilities with Deep 6 Acquisition
Tempus, a leading technology company in precision medicine, leverages artificial intelligence (AI) to advance healthcare. With one of the world’s largest multimodal data libraries and an operating system designed to make this data accessible and actionable, Tempus provides AI-enabled solutions that empower physicians to deliver personalized patient care. Simultaneously, the company facilitates the discovery, development, and delivery of optimal therapeutics.
By continuously gathering and analyzing data, Tempus enables physicians to benefit from insights derived from previous patient treatments. This approach ensures that each patient receives more informed, data-driven care.
The recent acquisition of Deep 6 further strengthens Tempus’ capabilities by enhancing its integration infrastructure. This expansion:
- Increases the number of healthcare providers connected to the Tempus platform
- Enhances the deployment of critical applications such as Next, which assists physicians in closing care gaps, and TIME, which helps patients access potentially life-saving clinical trials
“Deep 6’s impressive integration infrastructure is well-suited to complement our connectivity efforts, which are central to our ability to support physicians in delivering optimized care,” said Eric Lefkofsky, Founder and CEO of Tempus. “This acquisition broadens our reach, adding even more providers to our platform and further strengthening our mission to advance precision medicine.”
